SecProbe.io

<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 April 14, 2025

Lynn Stockwell
Chief Executive Officer
Drugs Made In America Acquisition II Corp.
1 East Broward Boulevard, Suite 700
Fort Lauderdale, FL 33301

 Re: Drugs Made In America Acquisition II Corp.
 Draft Registration Statement on Form S-1
 Submitted March 19, 2025
 CIK No.: 0002040475
Dear Lynn Stockwell:

 We have reviewed your draft registration statement and have the
following comments.

 Please respond to this letter by providing the requested information and
either
submitting an amended draft registration statement or publicly filing your
registration
statement on EDGAR. If you do not believe a comment applies to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

 After reviewing the information you provide in response to this letter
and your
amended draft registration statement or filed registration statement, we may
have additional
comments.

Draft Registration Statement on Form S-1
Cover page

1. We note your disclosure on page 15 and elsewhere that if you increase or
decrease the
 size of the offering, you will effect a share dividend or other
mechanism with respect
 to the founder shares so as to maintain the ownership of founder shares
by the initial
 shareholders at 20% of your issued and outstanding ordinary shares upon
 consummation of the offering. Please revise your cover page disclosure
to include this
 information, as well as the number of founder shares to be issued to
your officers
 and directors, which you reference on page 11. Please also revise to
provide cross-
 references to all the locations of related compensation disclosures. See
Item
 1602(a)(3) of Regulation S-K.
 April 14, 2025
Page 2
2. Please state there may be actual or potential material conflicts of
interest between the
 sponsor and its affiliates and purchasers in the offering, and provide a
highlighted
 cross-reference to the detailed disclosure in the prospectus. See Item
1602(a)(5) of
 Regulation S-K.
Summary, page 1

3. We note your disclosure on page 19 that you may extend the period of
time within
 which you must consummate an initial business combination. Please
disclose whether
 you expect to extend the time period and whether there are any
limitations on the
 number of extensions, including the number of times. Also disclose the
consequences
 to the sponsor of not completing an extension of this time period. See
Item 1602(b)(4)
 of Regulation S-K.
4. Please revise to expand your table on page 6 to also discuss the
potential issuance of
 shares as a result of the anti-dilution adjustment for the founder
shares and the founder
 shares to be issued to your officers and directors. See Item 1602(b)(6)
of Regulation
 S-K.
5. Please revise the table relating to transfer restrictions to also
discuss the lock-up
 required by the underwriter. In this regard, we note your disclosure on
page 157
 regarding lock-up provisions that would require the written consent of
the
 underwriters. In addition, expand the tabular disclosure to identify the
natural persons
 and entities subject to such agreements or arrangements. See Item
1603(a)(9) of
 Regulation S-K.
Summary of Risk Factors, page 32

6. Please revise by expanding the third bullet to also discuss the amount
of public shares
 that may be needed if only the minimum number of shares representing a
quorum are
 voted. We also note your disclosure on page 16 indicating that only 4.6%
of public
 shares may be needed to approve the initial business combination, and
your risk factor
 on page 38 indicating that you may not need "any" public shares. Please
revise your
 disclosures to reconcile, and clarify in your prospectus as appropriate
the required
 quorum for such a shareholder vote if it was by ordinary resolution.
Risk Factors, page 38

7. We note numerous exceptions to the transfer restrictions on page 129.
Please add risk
 factor disclosure about risks that may arise from the sponsor having the
ability to
 remove itself as your sponsor before identifying a business combination,
including
 through the unconditional ability to transfer the founder shares or
otherwise. Address
 the consequences of such removal to the company's ability to consummate
an initial
 business combination, including that any replacement sponsor could have
difficulty
 finding a target.
Provisions in our amended and restated memorandum. . ., page 58

8. Please expand this risk factor, and also add a summary risk factor in
your Summary
 section, to discuss the impact of having a classified board. In
addition, update your
 disclosure on page 119 to clarify the class of each director or director
nominee.
 April 14, 2025
Page 3

Dilution, page 85

9. Please expand your disclosure outside the table in this section to
highlight that you
 may need to issue additional securities as you intend to seek an initial
business
 combination with a target company with an enterprise value greater than
the net
 proceeds of the offering and the sale of private units, as stated on
page 9 of your
 prospectus.
Prior SPAC Experience, page 120

10. Please disclose the financing needed for the transaction by Insight
Acquisition Corp.
 Also, disclose the level of redemptions for Insight Acquisition Corp. in
the business
 combination with AMOD.
Conflicts of Interest, page 124

11. Please clarify in this section that your sponsor paid a nominal
aggregate purchase
 price of $35,000 for the 25,875,000 founder shares, or approximately
$0.0014 per
 share, and discuss the conflict that the founder shares and the private
units held by
 your sponsor and management will be worthless if you do not complete a
business
 combination transaction during the completion window. Also, disclose in
this section
 the conflicts of interest relating to repayment of loans and
reimbursements of
 expenses in the event you do not complete a deSPAC transaction. Refer to
Item
 1603(b) of Regulation S-K. Also, revise your disclosure in the summary
section to
 address the conflicts related to out-of-pocket expenses.
Restrictions on Transfers of Founder Shares and Private Units, page 129

12. Please disclose the circumstances under which the sponsor indirectly
could transfer
 ownership of your securities to third parties, by transfer of membership
interests in the
 sponsor or otherwise. See Item 1603(a)(6) of Regulation S-K.
 Please contact Babette Cooper at 202-551-3396 or Isaac Esquivel at
202-551-3395 if
you have questions regarding comments on the financial statements and related
matters. Please contact Ruairi Regan at 202-551-3269 or Dorrie Yale at
202-551-8776 with
any other questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Real
Estate & Construction
cc: Alex Weniger-Araujo, Esq.
</TEXT>
</DOCUMENT>